Beta Bionics, Inc. (NASDAQ:BBNX) Short Interest Down 24.0% in January

Beta Bionics, Inc. (NASDAQ:BBNX) was the recipient of a large decrease in short interest in the month of January. As of January 15th, there was short interest totaling 5,551,550 shares, a decrease of 24.0% from the December 31st total of 7,301,052 shares. Based on an average daily volume of 1,989,334 shares, the short-interest ratio is currently 2.8 days. Currently, 12.6% of the company’s stock are short sold. Currently, 12.6% of the company’s stock are short sold. Based on an average daily volume of 1,989,334 shares, the short-interest ratio is currently 2.8 days.

Beta Bionics Stock Down 6.5%

NASDAQ BBNX traded down $0.96 during trading hours on Friday, hitting $13.83. The company had a trading volume of 1,395,245 shares, compared to its average volume of 1,462,400. The firm has a market cap of $608.93 million and a P/E ratio of -3.16. Beta Bionics has a fifty-two week low of $8.89 and a fifty-two week high of $32.71. The business has a fifty day simple moving average of $25.98 and a 200-day simple moving average of $22.61.

Insider Buying and Selling at Beta Bionics

In other Beta Bionics news, CFO Stephen Feider sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $29.53, for a total value of $590,600.00. Following the completion of the transaction, the chief financial officer owned 42,614 shares in the company, valued at $1,258,391.42. This represents a 31.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mike Mensinger sold 2,200 shares of the stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $30.10, for a total transaction of $66,220.00. Following the completion of the sale, the insider directly owned 80,752 shares of the company’s stock, valued at $2,430,635.20. This trade represents a 2.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 32,490 shares of company stock valued at $960,835.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BBNX. Divisadero Street Capital Management LP acquired a new position in Beta Bionics during the 2nd quarter valued at about $13,817,000. Sands Capital Alternatives LLC boosted its holdings in shares of Beta Bionics by 15.0% in the second quarter. Sands Capital Alternatives LLC now owns 3,570,113 shares of the company’s stock valued at $51,981,000 after acquiring an additional 466,331 shares in the last quarter. Walleye Capital LLC increased its stake in shares of Beta Bionics by 47.3% during the second quarter. Walleye Capital LLC now owns 218,189 shares of the company’s stock valued at $3,177,000 after acquiring an additional 70,084 shares during the period. Values First Advisors Inc. raised its holdings in Beta Bionics by 13.2% during the second quarter. Values First Advisors Inc. now owns 42,563 shares of the company’s stock worth $620,000 after purchasing an additional 4,978 shares in the last quarter. Finally, Calamos Advisors LLC acquired a new stake in Beta Bionics in the third quarter worth approximately $642,000.

Analysts Set New Price Targets

Several brokerages have issued reports on BBNX. Wall Street Zen cut Beta Bionics from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. TD Cowen assumed coverage on Beta Bionics in a research report on Monday, January 26th. They set a “hold” rating and a $17.00 price target on the stock. Truist Financial raised their price objective on Beta Bionics from $32.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Bank of America lowered shares of Beta Bionics from a “buy” rating to a “neutral” rating in a research note on Friday, January 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Beta Bionics in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.27.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.